COVID‐19‐related medicine utilization study in pregnancy : The COVI‐PREG cohort
Aim The objective of this study was to describe the use of COVID‐19‐related medicines during pregnancy and their evolution between the early/late periods of the pandemic. Methods Pregnant women who tested positive for SARS‐CoV‐2 from March 2020 to July 2021 were included using the COVI‐PREG registry. Exposure to the following COVID‐19‐related medicines was recorded: antibiotics, antivirals, hydroxychloroquine, corticosteroids, anti‐interleukin‐6 and immunoglobulins. We described the prevalence of medicines used, by trimester of pregnancy, maternal COVID‐19 severity level and early/late period of the pandemic (before and after 1 July 2020). Findings We included 1964 pregnant patients who tested positive for SARS‐CoV‐2. Overall, 10.4% (205/1964) received at least one COVID‐19‐related medicine including antibiotics (8.6%; 169/1694), corticosteroids (3.2%; 62/1964), antivirals (2.0%; 39/1964), hydroxychloroquine (1.4%; 27/1964) and anti‐interleukin‐6 (0.3%; 5/1964). The use of at least one COVID‐19‐related medicine was 3.1% (12/381) in asymptomatic individuals, 4.2% (52/1233) in outpatients, 19.7% (46/233) in inpatients without oxygen, 72.1% (44/61) in those requiring standard oxygen, 95.7% (22/23) in those requiring high flow oxygen, 96.2% (25/26) in patients who required intubation and 57.1% (4/7) among patients who died. The proportion who received medicines to treat COVID‐19 was higher before than after July 2020 (16.7% vs. 7.7%). Antibiotics, antivirals and hydroxychloroquine had lower rates of use during the late period. Conclusion Medicine use in pregnancy increased with disease severity. The trend towards increased use of corticosteroids seems to be aligned with changing guidelines. Evidence is still needed regarding the effectiveness and safety of COVID‐19‐related medicines in pregnancy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:89 |
|---|---|
| Enthalten in: |
British Journal of Clinical Pharmacology - 89(2023), 5, Seite 1560-1574 |
| Beteiligte Personen: |
Favre, Guillaume [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 The British Pharmacological Society |
|---|
| Umfang: |
15 |
|---|
| doi: |
10.1111/bcp.15611 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY015147665 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY015147665 | ||
| 003 | DE-627 | ||
| 005 | 20231111131734.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/bcp.15611 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_BCP_2023_89_5.zip.xml |
| 035 | |a (DE-627)WLY015147665 | ||
| 035 | |a (WILEY)BCP15611 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Favre, Guillaume |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID‐19‐related medicine utilization study in pregnancy |b The COVI‐PREG cohort |
| 264 | 1 | |c 2023 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 The British Pharmacological Society | ||
| 520 | |a Aim The objective of this study was to describe the use of COVID‐19‐related medicines during pregnancy and their evolution between the early/late periods of the pandemic. Methods Pregnant women who tested positive for SARS‐CoV‐2 from March 2020 to July 2021 were included using the COVI‐PREG registry. Exposure to the following COVID‐19‐related medicines was recorded: antibiotics, antivirals, hydroxychloroquine, corticosteroids, anti‐interleukin‐6 and immunoglobulins. We described the prevalence of medicines used, by trimester of pregnancy, maternal COVID‐19 severity level and early/late period of the pandemic (before and after 1 July 2020). Findings We included 1964 pregnant patients who tested positive for SARS‐CoV‐2. Overall, 10.4% (205/1964) received at least one COVID‐19‐related medicine including antibiotics (8.6%; 169/1694), corticosteroids (3.2%; 62/1964), antivirals (2.0%; 39/1964), hydroxychloroquine (1.4%; 27/1964) and anti‐interleukin‐6 (0.3%; 5/1964). The use of at least one COVID‐19‐related medicine was 3.1% (12/381) in asymptomatic individuals, 4.2% (52/1233) in outpatients, 19.7% (46/233) in inpatients without oxygen, 72.1% (44/61) in those requiring standard oxygen, 95.7% (22/23) in those requiring high flow oxygen, 96.2% (25/26) in patients who required intubation and 57.1% (4/7) among patients who died. The proportion who received medicines to treat COVID‐19 was higher before than after July 2020 (16.7% vs. 7.7%). Antibiotics, antivirals and hydroxychloroquine had lower rates of use during the late period. Conclusion Medicine use in pregnancy increased with disease severity. The trend towards increased use of corticosteroids seems to be aligned with changing guidelines. Evidence is still needed regarding the effectiveness and safety of COVID‐19‐related medicines in pregnancy. | ||
| 700 | 1 | |a Gerbier, Eva |4 aut | |
| 700 | 1 | |a Maisonneuve, Emeline |4 aut | |
| 700 | 1 | |a Pomar, Léo |4 aut | |
| 700 | 1 | |a Winterfeld, Ursula |4 aut | |
| 700 | 1 | |a Lepigeon, Karine |4 aut | |
| 700 | 1 | |a Bloemenkamp, Kitty W. M. |4 aut | |
| 700 | 1 | |a Bruin, Odette |4 aut | |
| 700 | 1 | |a Hurley, Eimir |4 aut | |
| 700 | 1 | |a Nordeng, Hedvig |4 aut | |
| 700 | 1 | |a Siiskonen, Satu J. |4 aut | |
| 700 | 1 | |a Sturkenboom, Miriam C. J. M. |4 aut | |
| 700 | 1 | |a Baud, David |4 aut | |
| 700 | 1 | |a Panchaud, Alice |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British Journal of Clinical Pharmacology |g 89(2023), 5, Seite 1560-1574 |w (DE-627)WLY00261751X |x 13652125 |7 nnns |
| 773 | 1 | 8 | |g volume:89 |g year:2023 |g number:5 |g pages:1560-1574 |g extent:15 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 89 |j 2023 |e 5 |h 1560-1574 |g 15 | ||